A European partner in Life Science

Healthcare 21 was established twenty-two years ago as a 21st-century solution for healthcare products and services. From the very beginning, ‘the caring company’ was born, and the culture has always been fundamental to the HC21 business with passionate, dedicated, and committed teams who deliver the best products and services across 15 different therapeutic areas in the Irish market. 

Healthcare 21 has been a great addition to the AddLife family. The teams at HC21 have truly embraced the AddLife culture, delivering on our important metrics.

Watch the video here:

My decision to join the AddLife family was based on the experiences of entrepreneurs who had already joined. Their positive feedback gave me the confidence to join. The formal due diligence was, as expected, thorough and standardised, but what stood out was AddLife’s approach: before diving into numbers, they focused on people, culture, and values. Even with a decentralised model, there is a strong, shared culture that brings everyone together.

When it comes to selling your company, it’s easy to focus solely on the numbers and the offer on the table. However, the real value of such a decision goes far beyond the financial aspects. It’s about people. It’s about finding a partner who will not only honour the legacy you’ve built but also create a future for your employees to thrive and grow. For me, that partner was AddLife.

When we began considering the future of BioCat, I realized that selling the company was about much more than just the numbers. While the financial side is important, what really mattered was finding a partner who would respect our values, support our team, and help us continue building on our strong foundation.

Margin improvements remain the highest priority, and during the quarter, profitability was clearly strengthened in both business areas. The margin improvements are mainly driven by ongoing efficiency initiatives, a continuous shift in the product portfolio towards more advanced, as well as active pricing efforts. Organic growth in the quarter was driven by positive developments in both business areas. Our acquisitions have developed well, with strong growth, improved margins, and significantly improved cash flows. Profit for the period improved by 228 percent in the quarter.